Related Experiment Video
Updated: Jun 28, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
Multiple indications for anti-inflammatory apolipoprotein mimetic peptides
Brian J Van Lenten1, Mohamad Navab, G M Anantharamaiah
1David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, USA. bvanlent@mednet.ucla.edu
Apolipoprotein mimetic peptides show promise for treating atherosclerosis and other inflammatory diseases. These peptides effectively reduce vascular inflammation in animal models, suggesting broad therapeutic potential.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Atherosclerosis is a major vascular inflammatory condition.
- Apolipoprotein mimetic peptides are under investigation for therapeutic applications.
- Vascular inflammation underlies various chronic diseases.
Purpose of the Study:
- To evaluate the efficacy of apolipoprotein mimetic peptides in atherosclerosis models.
- To explore the potential of these peptides in other inflammatory conditions.
Main Methods:
- Studies utilized animal models of atherosclerosis.
- Further investigations included models of viral influenza, asthma, and other inflammatory disorders.
Main Results:
- Apolipoprotein mimetic peptides significantly reduced atherosclerosis in animal models.
- Preliminary studies suggest efficacy in diverse inflammatory conditions.
Conclusions:
- Apolipoprotein mimetic peptides represent a potential therapeutic strategy for atherosclerosis.
- These peptides may offer a broad-spectrum treatment for various inflammatory diseases.
More Related Videos
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Related Concept Videos
Cross-reactivity
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF